GlassScriptPhysician profile
Sherlene Trotman
NPI 1902040793
$8,735.96
in general payments reported to CMS, 2019-2025
32 companies · $2,609 in 2025
The $2,609 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $276 · 2021: $1,128 · 2022: $1,292 · 2023: $1,412 · 2024: $1,875 · 2025: $2,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,806 · Education: $89.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,805.82 |
| Education | $89.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,448.51 | 2021-2025 | Watchman Flx, Versacross Access Solution, Farapulse |
| Astrazeneca Pharmaceuticals LP | $1,380.94 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $766.04 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $555.60 | 2022-2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $481.89 | 2022-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $439.29 | 2022-2025 | Pressurewire, Mitraclip, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.33 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $372.12 | 2023-2025 | |
| Medtronic, INC. | $341.55 | 2021-2024 | Linq II, Corevalve Evolut R |
| Amgen INC. | $268.36 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $266.10 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.78 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $233.03 | 2022-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $212.25 | 2023-2025 | Verquvo, Capvaxive |
| Shockwave Medical, INC | $200.81 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $172.54 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $114.27 | 2021 | |
| Xeris Pharmaceuticals, INC. | $111.34 | 2025 | Recorlev |
| Kestra Medical Technology Services, INC. | $110.34 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $88.88 | 2021-2022 | |
| Bridgebio Pharma, INC. | $70.49 | 2025 | Attruby |
| Abiomed | $65.96 | 2023-2025 | Impella |
| Lilly USA, LLC | $65.53 | 2019-2021 | |
| Scpharmaceuticals INC. | $54.54 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $46.08 | 2023-2024 | Inpefa |
| Irhythm Technologies, INC. | $41.10 | 2024 | Zio Monitor, Zio Xt Patch |
| Medicomp INC | $37.55 | 2025 | Telepatch Cardiac Monitor |
| Heartflow, INC. | $32.32 | 2025 | |
| Exelixis INC. | $27.11 | 2020 | |
| Lantheus Medical Imaging, INC. | $20.84 | 2023 | Definity |
| Renalytix Ai, INC. | $18.97 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sanofi Pasteur INC. | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherlene Trotman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.